FR10C0024I2 - Liquid formulations containing a gonadotropin - Google Patents

Liquid formulations containing a gonadotropin

Info

Publication number
FR10C0024I2
FR10C0024I2 FR10C0024C FR10C0024C FR10C0024I2 FR 10C0024 I2 FR10C0024 I2 FR 10C0024I2 FR 10C0024 C FR10C0024 C FR 10C0024C FR 10C0024 C FR10C0024 C FR 10C0024C FR 10C0024 I2 FR10C0024 I2 FR 10C0024I2
Authority
FR
France
Prior art keywords
gonadotropin
formulations containing
liquid formulations
liquid
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0024C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of FR10C0024I1 publication Critical patent/FR10C0024I1/fr
Application granted granted Critical
Publication of FR10C0024I2 publication Critical patent/FR10C0024I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
FR10C0024C 1997-01-15 2010-04-16 Liquid formulations containing a gonadotropin Active FR10C0024I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200099 1997-01-15
EP98200068A EP0853945B1 (en) 1997-01-15 1998-01-13 Liquid gonadotropin containing formulations

Publications (2)

Publication Number Publication Date
FR10C0024I1 FR10C0024I1 (en) 2010-05-21
FR10C0024I2 true FR10C0024I2 (en) 2011-04-01

Family

ID=8227932

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0024C Active FR10C0024I2 (en) 1997-01-15 2010-04-16 Liquid formulations containing a gonadotropin

Country Status (30)

Country Link
US (1) US5929028A (en)
EP (2) EP0853945B1 (en)
JP (1) JP4353549B2 (en)
KR (1) KR100498531B1 (en)
CN (1) CN1165341C (en)
AR (1) AR011410A1 (en)
AT (1) ATE237348T1 (en)
AU (1) AU736339B2 (en)
BR (1) BR9800323B1 (en)
CA (1) CA2226803A1 (en)
CZ (1) CZ297419B6 (en)
DE (2) DE122010000011I1 (en)
DK (1) DK0853945T3 (en)
ES (1) ES2196474T3 (en)
FR (1) FR10C0024I2 (en)
HK (1) HK1010150A1 (en)
HU (1) HU227154B1 (en)
ID (1) ID19499A (en)
IL (1) IL122732A0 (en)
LU (1) LU91655I2 (en)
MX (1) MX9800438A (en)
NO (3) NO322509B1 (en)
NZ (1) NZ329572A (en)
PL (1) PL190103B1 (en)
PT (1) PT853945E (en)
RU (1) RU2203086C2 (en)
SA (1) SA98181124B1 (en)
TR (1) TR199800062A2 (en)
TW (1) TW518235B (en)
ZA (1) ZA9883B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
BR9912243A (en) * 1998-07-23 2001-10-16 Lilly Co Eli Fsh formulations and fsh variants, products and processes
JP2007204498A (en) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd Long-term stabilized formulations
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
HUP0202189A3 (en) * 1999-07-12 2003-07-28 Sandoz Ag Growth hormone formulations, method for their preparation and device and kit comprising thereof
KR100808149B1 (en) * 2000-02-22 2008-02-29 라보라토리스 세로노 에스.에이. Purified ??
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
AU2007200662A1 (en) * 2001-08-30 2007-03-08 Kirin-Amgen, Inc. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1346843A1 (en) * 2002-03-22 2003-09-24 Fuji Photo Film Co., Ltd. Image forming method
EP1610803B8 (en) 2003-03-04 2011-09-14 AspenBio Pharma, Inc. LH for use in maintaining one or more pregnancies by inducing accessory corpus luteum formation.
KR101105486B1 (en) * 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
DK1638595T3 (en) * 2003-06-20 2013-04-08 Ares Trading Sa Freeze-dried FSH / LH formulations
JP4412989B2 (en) * 2003-12-15 2010-02-10 株式会社日立製作所 Data processing system having a plurality of storage systems
KR100587535B1 (en) * 2004-02-04 2006-06-08 충남대학교산학협력단 A Recombinant hFSH Gene, and An Expression Vector Containing Thereof
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
KR101105871B1 (en) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 hFSF Aqueous Formulation
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20090261690A1 (en) * 2006-09-25 2009-10-22 Tomoaki Mashimo Ultrasonic wave handling device and a microscopic in-tube inspection system
KR20080106636A (en) * 2007-06-04 2008-12-09 동아제약주식회사 Injectable ready to use solutions comprising human chorionic gonadotropin
MX2009013886A (en) * 2007-06-25 2010-01-27 Amgen Inc Compositions of specific binding agents to hepatocyte growth factor.
WO2009000913A1 (en) 2007-06-28 2008-12-31 Biogenerix Ag Fsh producing cell clone
MY153976A (en) * 2007-11-01 2015-04-30 Merck Serono Sa Lh liquid formulations
CN104688679A (en) * 2008-02-08 2015-06-10 拉蒂奥法姆有限责任公司 Liquid formulation of fsh
TWI488640B (en) 2008-04-16 2015-06-21 Ferring Int Ct Sa Pharmaceutical preparation
CN102309745B (en) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 Glycoprotein composition which almost does not contain subunit
CN101347613B (en) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 Composition of glucoprotein containing nearly no subunit and preparation method thereof
JP5554244B2 (en) 2008-11-04 2014-07-23 あすか製薬株式会社 Aqueous composition containing follicle stimulating hormone
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI604850B (en) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012127501A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
CN103619358B (en) 2011-03-31 2017-02-15 辉凌公司 Pharmaceutical preparation
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
JO3092B1 (en) 2011-08-08 2017-03-15 Ferring Bv Composition for controlled ovarian stimulation
PE20142405A1 (en) 2012-04-19 2015-01-25 Opko Biolog Ltd LONG-ACTING OXYTOMODULIN VARIANTS AND METHODS OF PRODUCING THEM
MX2015004940A (en) 2012-10-18 2015-12-09 Neuralight Hd Llc Treatment of depression and ptsd.
BR122020018510B1 (en) 2012-11-20 2023-03-14 Opko Biologics Ltd METHOD FOR INCREMENTALLY INCREASE THE HYDRODYNAMIC SIZE OF AN ACTIVATED COAGULATION FACTOR VIIA
ES2694328T3 (en) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US20160250295A1 (en) 2013-11-12 2016-09-01 Cadila Healthcare Limited Formulation for gonadotropins
HUE056178T2 (en) * 2014-10-21 2022-01-28 Hexima Ltd A method of treatment of fungal infections
WO2016203482A2 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3432916B1 (en) 2016-09-13 2019-08-14 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US20220143131A1 (en) 2019-05-16 2022-05-12 Ceva Sante Animale Compositions and Methods for increasing Reproduction Performance in Non Human Mammals Using Recombinant Luteinizing Hormone
CN112451652A (en) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 Recombinant human thyrotropin injection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357934A (en) * 1980-07-23 1982-11-09 The Curators Of The University Of Missouri Method of treating male infertility
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IT1206302B (en) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca URINARY FOLLICLE-STIMULATING HORMONE
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
EP0461200B1 (en) * 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1250075B (en) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca PHARMACEUTICAL COMPOSITIONS CONTAINING GONADOTROPINE.
EP0639202B1 (en) * 1992-04-30 1998-11-25 Cor Therapeutics, Inc. Stable polypeptide composition
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
PT814841E (en) * 1995-03-21 2002-03-28 Applied Research Systems HCG LIQUID FORMULATIONS

Also Published As

Publication number Publication date
EP0853945A1 (en) 1998-07-22
CN1165341C (en) 2004-09-08
IL122732A0 (en) 1998-08-16
DE69813322D1 (en) 2003-05-22
NO2010013I2 (en) 2015-05-18
ATE237348T1 (en) 2003-05-15
BR9800323B1 (en) 2011-04-19
KR100498531B1 (en) 2005-09-30
AU736339B2 (en) 2001-07-26
CZ297419B6 (en) 2006-12-13
KR19980070493A (en) 1998-10-26
TW518235B (en) 2003-01-21
DK0853945T3 (en) 2003-08-04
EP1285665A1 (en) 2003-02-26
NO2021001I1 (en) 2021-01-12
ID19499A (en) 1998-07-16
AU5205998A (en) 1998-07-23
PL190103B1 (en) 2005-10-31
LU91655I2 (en) 2010-04-26
NO980177D0 (en) 1998-01-14
SA98181124B1 (en) 2006-07-10
CN1191139A (en) 1998-08-26
PT853945E (en) 2003-08-29
CA2226803A1 (en) 1998-07-15
HK1010150A1 (en) 1999-06-17
DE122010000011I1 (en) 2010-07-08
FR10C0024I1 (en) 2010-05-21
CZ13598A3 (en) 1998-08-12
NO322509B1 (en) 2006-10-16
HUP9800056A3 (en) 2001-01-29
RU2203086C2 (en) 2003-04-27
HU227154B1 (en) 2010-08-30
US5929028A (en) 1999-07-27
AR011410A1 (en) 2000-08-16
BR9800323A (en) 1999-06-29
MX9800438A (en) 1998-11-30
PL324279A1 (en) 1998-07-20
HUP9800056A2 (en) 1998-08-28
NZ329572A (en) 1999-05-28
NO2010013I1 (en) 2010-06-07
DE69813322T2 (en) 2004-02-19
EP0853945B1 (en) 2003-04-16
TR199800062A2 (en) 1998-08-21
JP4353549B2 (en) 2009-10-28
ES2196474T3 (en) 2003-12-16
JPH10203997A (en) 1998-08-04
HU9800056D0 (en) 1998-03-02
ZA9883B (en) 1998-07-08
NO980177L (en) 1998-07-16

Similar Documents

Publication Publication Date Title
FR10C0024I2 (en) Liquid formulations containing a gonadotropin
ATE252631T1 (en) WATER-FREE LIQUID DETERGENT COMPOSITIONS CONTAINING SPRACHES
ATE318298T1 (en) LIQUID ACTIVATED BLEACH COMPOSITIONS
MA24466A1 (en) COMPOSITIONS CONTAINING TETRAHYDROLISTATIN
DE69816335D1 (en) CYCLOSPORIN CONTAINING MICROEMULSION PRE-CONCENTRATE COMPOSITION
BR9607754A (en) Liquid detergent composition
FR2766161B1 (en) CARTRIDGE CONTAINING TWO LIQUIDS
FR2763152B1 (en) FLOODLESS LIQUID COUNTER
MA23153A1 (en) LIQUID DETERGENT COMPOSITION CONTAINING AN INSECTICIDE
MA23684A1 (en) LIQUID ANTIACID COMPOSITIONS
DE69802424D1 (en) EXHIBITION CONTAINER
DE69524127D1 (en) Liquid developer composition
DE59604664D1 (en) Liquid container
IT1299224B1 (en) LIQUID MULTI-PURPOSE ADDITIVES
DE69711182T2 (en) PRE-NON-AQUEOUS LIQUID DETERGENT COMPOSITIONS CONTAINING BLEACH
FR2737219B1 (en) LIQUID CLEANING COMPOSITION
FR2773168B1 (en) LIQUID BLEACHING COMPOSITION
IT1289623B1 (en) GELIFIED COMPOSITIONS CONTAINING ORGANIC LIQUIDS
DE69802843D1 (en) Liquid dye composition
DE29706926U1 (en) Liquid detergent
KR970015984U (en) Manicure combined cleaning liquid container
DE29702507U1 (en) Liquid container
DE69904021T2 (en) LIQUID PHARMACEUTICAL PREPARATION CONTAINING ZOTEPIN
KR970051708U (en) Stackable liquid container
MA23525A1 (en) GRANULAR DETERGENT COMPOSITIONS CONTAINING AN AMYLASE